WO2009017236A1 - ピリドピリミジン－４－オン誘導体 - Google Patents

ピリドピリミジン－４－オン誘導体 Download PDF

Info

Publication number
WO2009017236A1
WO2009017236A1 PCT/JP2008/063916 JP2008063916W WO2009017236A1 WO 2009017236 A1 WO2009017236 A1 WO 2009017236A1 JP 2008063916 W JP2008063916 W JP 2008063916W WO 2009017236 A1 WO2009017236 A1 WO 2009017236A1
Authority
WO
WIPO (PCT)
Prior art keywords
disease
pyridopyrimidin
cerebral
derivatives
depilation
Prior art date
Application number
PCT/JP2008/063916
Other languages
English (en)
French (fr)
Inventor
Takeshi Kuwada
Dai Nozawa
Tomoko Ishizaka
Mitsukane Yoshinaga
Kensei Yoshikawa
Original Assignee
Taisho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co., Ltd. filed Critical Taisho Pharmaceutical Co., Ltd.
Publication of WO2009017236A1 publication Critical patent/WO2009017236A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

一般式（１）で表されるピリドピリミジン－４－オン誘導体、又はその医薬上許容される塩は、アルギニン－バソプレッシン１ｂ受容体拮抗作用を有し、うつ病、不安障害、統合失調症、アルツハイマー病、パーキンソン病、ハンチントン舞踏病、摂食障害、高血圧、消化器疾患、薬物依存症、てんかん、脳梗塞、脳虚血、脳浮腫、頭部外傷、炎症、免疫関連疾患、脱毛症等の疾患の治療又は予防剤として有用である。 【化１】
PCT/JP2008/063916 2007-08-01 2008-08-01 ピリドピリミジン－４－オン誘導体 WO2009017236A1 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007-201246 2007-08-01
JP2007201246 2007-08-01
JP2008051182A JP2010229035A (ja) 2007-08-01 2008-02-29 ピリドピリミジン−４−オン誘導体
JP2008-051182 2008-02-29

Publications (1)

Publication Number Publication Date
WO2009017236A1 true WO2009017236A1 (ja) 2009-02-05

Family

ID=40304463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/063916 WO2009017236A1 (ja) 2007-08-01 2008-08-01 ピリドピリミジン－４－オン誘導体

Country Status (2)

Country Link
JP (1) JP2010229035A (ja)
WO (1) WO2009017236A1 (ja)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009130231A1 (en) * 2008-04-24 2009-10-29 Glaxo Group Limited Pyrrolo [1, 2-a] pyrazine derivatives as vasopressin vib receptor antagonists
JP2010173978A (ja) * 2009-01-30 2010-08-12 Taisho Pharmaceutical Co Ltd ピリドピリミジン−４−オン誘導体
WO2011045258A1 (en) * 2009-10-13 2011-04-21 N.V. Organon Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor
WO2011096461A1 (ja) * 2010-02-03 2011-08-11 大正製薬株式会社 キノリン誘導体
WO2012043791A1 (ja) 2010-10-01 2012-04-05 大正製薬株式会社 １，２，４-トリアゾロン誘導体
WO2013062027A1 (ja) 2011-10-27 2013-05-02 大正製薬株式会社 アゾール誘導体
WO2013147117A1 (ja) 2012-03-30 2013-10-03 大正製薬株式会社 縮環アゾール誘導体
JP2014224108A (ja) * 2013-04-26 2014-12-04 大正製薬株式会社 アゾール誘導体を含有する医薬
JP2015120644A (ja) * 2013-12-20 2015-07-02 大正製薬株式会社 Ｖ１ｂ受容体の放射性標識リガンド
JPWO2013191244A1 (ja) * 2012-06-21 2016-05-26 大正製薬株式会社 ピリドピリミジン−４−オン誘導体

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104031777A (zh) * 2014-06-12 2014-09-10 仇彩霞 一种培养皿洗涤液及其洗涤步骤

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006095014A1 (en) * 2005-03-11 2006-09-14 N.V. Organon 2- (4-0x0-4h-quinaz0lin-3-yl) acetamides and their use as vasopressin v3 antagonists
JP2007176809A (ja) * 2005-12-27 2007-07-12 Hideaki Natsukari 複素環置換アミド化合物、その製造法および医薬組成物
WO2007104034A2 (en) * 2006-03-08 2007-09-13 Takeda San Diego, Inc. Glucokinase activators
WO2008033764A2 (en) * 2006-09-11 2008-03-20 N.V. Organon Quinazolinone and isoquinolinone acetamide derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006095014A1 (en) * 2005-03-11 2006-09-14 N.V. Organon 2- (4-0x0-4h-quinaz0lin-3-yl) acetamides and their use as vasopressin v3 antagonists
JP2007176809A (ja) * 2005-12-27 2007-07-12 Hideaki Natsukari 複素環置換アミド化合物、その製造法および医薬組成物
WO2007104034A2 (en) * 2006-03-08 2007-09-13 Takeda San Diego, Inc. Glucokinase activators
WO2008033764A2 (en) * 2006-09-11 2008-03-20 N.V. Organon Quinazolinone and isoquinolinone acetamide derivatives

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009130231A1 (en) * 2008-04-24 2009-10-29 Glaxo Group Limited Pyrrolo [1, 2-a] pyrazine derivatives as vasopressin vib receptor antagonists
JP2010173978A (ja) * 2009-01-30 2010-08-12 Taisho Pharmaceutical Co Ltd ピリドピリミジン−４−オン誘導体
WO2011045258A1 (en) * 2009-10-13 2011-04-21 N.V. Organon Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor
CN102666540A (zh) * 2009-10-13 2012-09-12 Msd欧斯股份有限公司 用于治疗乙酰胆碱受体相关疾病的稠合吖嗪衍生物
JP2013507417A (ja) * 2009-10-13 2013-03-04 エム・エス・ディー・オス・ベー・フェー アセチルコリン受容体に関連する疾患の処置のための縮合アジン誘導体
US8841289B2 (en) 2009-10-13 2014-09-23 Merck Sharp & Dohme B.V. Heterocyclic derivatives
WO2011096461A1 (ja) * 2010-02-03 2011-08-11 大正製薬株式会社 キノリン誘導体
WO2012043791A1 (ja) 2010-10-01 2012-04-05 大正製薬株式会社 １，２，４-トリアゾロン誘導体
US9193695B2 (en) 2010-10-01 2015-11-24 Taisho Pharmaceutical Co., Ltd. 1, 2, 4-triazolone derivative and use thereof as an antagonist on the arginine-vasopressin 1B receptor
KR20140081824A (ko) 2011-10-27 2014-07-01 다이쇼 세이야꾸 가부시끼가이샤 아졸 유도체
CN103889951A (zh) * 2011-10-27 2014-06-25 大正制药株式会社 唑类衍生物
JPWO2013062027A1 (ja) * 2011-10-27 2015-04-02 大正製薬株式会社 アゾール誘導体
WO2013062027A1 (ja) 2011-10-27 2013-05-02 大正製薬株式会社 アゾール誘導体
CN103889951B (zh) * 2011-10-27 2016-12-14 大正制药株式会社 唑类衍生物
US9522914B2 (en) 2011-10-27 2016-12-20 Taisho Pharmaceutical Co., Ltd Azole derivative
RU2622639C2 (ru) * 2011-10-27 2017-06-19 Тайсо Фармасьютикал Ко., Лтд. Производные азолов
WO2013147117A1 (ja) 2012-03-30 2013-10-03 大正製薬株式会社 縮環アゾール誘導体
CN104185625A (zh) * 2012-03-30 2014-12-03 大正制药株式会社 稠环唑类衍生物
JPWO2013191244A1 (ja) * 2012-06-21 2016-05-26 大正製薬株式会社 ピリドピリミジン−４−オン誘導体
JP2014224108A (ja) * 2013-04-26 2014-12-04 大正製薬株式会社 アゾール誘導体を含有する医薬
JP2015120644A (ja) * 2013-12-20 2015-07-02 大正製薬株式会社 Ｖ１ｂ受容体の放射性標識リガンド

Also Published As

Publication number Publication date
JP2010229035A (ja) 2010-10-14

Similar Documents

Publication Publication Date Title
WO2009017236A1 (ja) ピリドピリミジン－４－オン誘導体
MX2014005140A (es) Derivado de azol.
MX2013006715A (es) Derivado de pirazol.
WO2009040331A3 (en) Amidine, thiourea and guanidine derivatives of 2-aminobenzothiazoles and aminobenzothiazines for their use as pharmacological agents for the treatment of neurodegenerative pathologies
WO2010088408A3 (en) Subunit selective nmda receptor antagonists for the treatment of neurological conditions
NZ629944A (en) Fused azole derivative
ME00954B (me) Aminoheterociklični spojevi
TW201144302A (en) 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds
WO2005089753A3 (en) Daao inhibiting bξnzisoxazoles and their use for the treatment of mental disorders
WO2007039462A3 (en) Indane derivatives as mch receptor antagonists
MX2013003633A (es) Derivado de 1, 2, 4-triazolona.
TR201909277T4 (tr) Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları.
GB2462235A (en) NMDA and MC receptor antagonists exhibiting neuroprotective and memory enhancing activities
MX2018012442A (es) Profarmaco de derivado de aminoacido.
WO2008111590A3 (en) Ampa and nmda receptor antagonists for neurodegenerative diseases
WO2011143469A8 (en) Therapeutic regimens
PH12014502670A1 (en) Prodrug of fluorine - containing amino acid
WO2009007300A3 (en) Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
WO2005107752A3 (en) Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
WO2007050353A3 (en) Tricyclic compounds useful as oxytocin receptor agonists
WO2007133983A3 (en) 2-aminobenzimidazoles for treating neurodegenerative diseases
WO2005067931A3 (en) Dopamine uptake inhibitors for the treatment of neurological disease
EA201171087A1 (ru) СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ
WO2006079077A3 (en) Use of diltiazem or analogs thereof as modulators of ghrelin receptor
IL185410A0 (en) Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of parkinson's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08792127

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08792127

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP